Compare Novo Nordisk A/S (NVO) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ZIM Integrated Shipping Services Ltd — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while ZIM Integrated Shipping Services Ltd trades at $24.99 (market cap $2.93B). The key difference: Novo Nordisk A/S is far larger — about 75.3× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| NVO | ZIM | |
|---|---|---|
Market Cap | $220.53B | $2.93B |
Sector | Health | Industrials |
52-Week High | $71.70 | $29.27 |
52-Week Low | $35.29 | $12.44 |
Enterprise Value | $239.49B | $6.78B |
Dividend Yield | 3.63% | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
ZIM trades at $24.31, showing minimal daily movement. The stock faces a bearish technical outlook with mixed earnings, including a Q1 2026 miss. Financially, it maintains a strong cash position and low valuation multiples, but profitability has declined from 2025 to 2026. Recent news is dominated by merger uncertainty with Hapag-Lloyd and leadership changes.
The outlook is cautious due to regulatory risks around the merger and volatile shipping rates. Upside exists if the deal proceeds or freight markets tighten, but downside risk is significant if the merger fails, with analyst targets near $16.75. High cash burn and insider selling add to near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
